Yongliang Jiang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yongliang Jiang has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
Cheng Li
Department of Respiratory and Critical Care Medicine, Hunan Provincial People’s Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, China
5 shared publicationsGang Jiang
Department of Respiratory and Critical Care Medicine, Hunan Provincial People’s Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, China
5 shared publicationsChao Li
Department of Respiratory and Critical Care Medicine, Hunan Provincial People’s Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, China
3 shared publicationsHui Zhang
Department of Respiratory and Critical Care Medicine, Hunan Provincial People’s Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, China
3 shared publicationsXiao Hu
Department of Respiratory and Critical Care Medicine, Hunan Provincial People’s Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, China
3 shared publicationsWeixia Xuan
Department of Respiratory and Critical Care Medicine, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou, Henan, China
2 shared publications
Latest Publications
- Open Access
- 6 July 2026
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 26 (1)
A novel percutaneous aspiration sclerotherapy for staged volume reduction of giant single bulla in the treatment of COPD combined with pulmonary bullae
The efficacy of a novel technique-percutaneous aspiration sclerotherapy for staged volume reduction of giant single bulla-in patients with chronic obstruct
- 6 July 2026
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 26 (1)
Open AccessA novel percutaneous aspiration sclerotherapy for staged volume reduction of giant single bulla in the treatment of COPD combined with pulmonary bullae
The efficacy of a novel technique-percutaneous aspiration sclerotherapy for staged volume reduction of giant single bulla-in patients with chronic obstruct
- Open Access
- 8 October 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1693942
Case Report: A case of giant emphysematous bullae successfully treated with percutaneous aspiration and sclerotherapy for staged reduction of pulmonary bullae
Giant emphysematous bullae (GEB) in COPD patients typically require high-risk surgery, with limited and minimally invasive alternatives. This report describes a 70-year-old man with COPD GOLD 3 and bilateral GEB (dominant bulla 8.5 cm× 6.2 cm) who underwent a novel percutaneous serial sclerotherapy protocol: Under CT guidance, a puncture needle was inserted into the bulla cavity on 3 consecutive days, with daily instillation of polidocanol (total 30 mL) and attempted air aspiration (successfully retrieving 1,000 mL of gas on day 3). No pneumothorax, desaturation, or bleeding occurred peri-procedurally. A follow-up CT scan at 3 months demonstrated>70% bullae volume reduction with lung re-expansion, correlating with significant clinical improvement. This first-reported percutaneous aspiration and sclerotherapy for staged reduction of pulmonary bullae (PASS) approach offers a safe, effective, minimally invasive option for GEB management in surgically high-risk COPD patients, warranting further validation of the protocol.
- 8 October 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1693942
Open AccessCase Report: A case of giant emphysematous bullae successfully treated with percutaneous aspiration and sclerotherapy for staged reduction of pulmonary bullae
Giant emphysematous bullae (GEB) in COPD patients typically require high-risk surgery, with limited and minimally invasive alternatives. This report describes a 70-year-old man with COPD GOLD 3 and bilateral GEB (dominant bulla 8.5 cm× 6.2 cm) who underwent a novel percutaneous serial sclerotherapy protocol: Under CT guidance, a puncture needle was inserted into the bulla cavity on 3 consecutive days, with daily instillation of polidocanol (total 30 mL) and attempted air aspiration (successfully retrieving 1,000 mL of gas on day 3). No pneumothorax, desaturation, or bleeding occurred peri-procedurally. A follow-up CT scan at 3 months demonstrated>70% bullae volume reduction with lung re-expansion, correlating with significant clinical improvement. This first-reported percutaneous aspiration and sclerotherapy for staged reduction of pulmonary bullae (PASS) approach offers a safe, effective, minimally invasive option for GEB management in surgically high-risk COPD patients, warranting further validation of the protocol.
- Open Access
- 1 July 2025
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 20, 2371-2379
Novel Laser System-Assisted CT-Guided Percutaneous Transthoracic Lung Biopsy in Patients with COPD Combined with Pulmonary Nodules
Objective: The diagnosis and management of pulmonary nodules in patients with COPD are challenging, as these nodules may represent either lung cancer or other pulmonary diseases. This study aims to evaluate the efficiency of a novel laser systems (LGS)-assisted CT-guided percutaneous lung biopsy in COPD patients with pulmonary nodules. Methods: A retrospective analysis was conducted on the data of 60 COPD patients with pulmonary nodules. Thirty patients (n=30) underwent CT-guided percutaneous transthoracic lung biopsy assisted by LGS, while the remaining 30 (n=30) underwent conventional manual CT-guided percutaneous transthoracic lung biopsy. The surgical time, number of punctures, CT scan frequency, and complications were compared between the two groups. Results: No significant differences were found between the two groups in terms of clinical characteristics, lesion size, location, puncture depth, or nodule nature. Compared to the traditional method, LGS-assisted CT-guided percutaneous lung biopsy significantly reduced the number of CT scans (2.3 ± 0.5 vs 3.2 ± 0.6, P < 0.001) and the average procedure time (12.6 ± 2.7 min vs 25.1 ± 3.4 min, P < 0.001). Additionally, the total intraoperative time per procedure was significantly reduced (25.1 ± 3.4 min vs 45.9 ± 8.8 min, P < 0.001). With the use of LGS, 73% (22/30) of the procedures hit the target on the first needle insertion, compared to only 6.7% (2/30) in the conventional group. Furthermore, there was no significant difference in the incidence of complications between the two groups. Conclusion: Compared to the traditional method, the use of LGS improved puncture efficiency in COPD patients, reduced the need for needle adjustments, and effectively shortened the procedure time.
- 1 July 2025
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 20, 2371-2379
Open AccessNovel Laser System-Assisted CT-Guided Percutaneous Transthoracic Lung Biopsy in Patients with COPD Combined with Pulmonary Nodules
Objective: The diagnosis and management of pulmonary nodules in patients with COPD are challenging, as these nodules may represent either lung cancer or other pulmonary diseases. This study aims to evaluate the efficiency of a novel laser systems (LGS)-assisted CT-guided percutaneous lung biopsy in COPD patients with pulmonary nodules. Methods: A retrospective analysis was conducted on the data of 60 COPD patients with pulmonary nodules. Thirty patients (n=30) underwent CT-guided percutaneous transthoracic lung biopsy assisted by LGS, while the remaining 30 (n=30) underwent conventional manual CT-guided percutaneous transthoracic lung biopsy. The surgical time, number of punctures, CT scan frequency, and complications were compared between the two groups. Results: No significant differences were found between the two groups in terms of clinical characteristics, lesion size, location, puncture depth, or nodule nature. Compared to the traditional method, LGS-assisted CT-guided percutaneous lung biopsy significantly reduced the number of CT scans (2.3 ± 0.5 vs 3.2 ± 0.6, P < 0.001) and the average procedure time (12.6 ± 2.7 min vs 25.1 ± 3.4 min, P < 0.001). Additionally, the total intraoperative time per procedure was significantly reduced (25.1 ± 3.4 min vs 45.9 ± 8.8 min, P < 0.001). With the use of LGS, 73% (22/30) of the procedures hit the target on the first needle insertion, compared to only 6.7% (2/30) in the conventional group. Furthermore, there was no significant difference in the incidence of complications between the two groups. Conclusion: Compared to the traditional method, the use of LGS improved puncture efficiency in COPD patients, reduced the need for needle adjustments, and effectively shortened the procedure time.
- Open Access
- 28 December 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-16
Hypoxia-induced TPC2 transcription and glycosylation aggravates pulmonary arterial hypertension by blocking autophagy flux
Pulmonary arterial hypertension (PAH) is a serious medical condition that causes a failure in the right heart. Two-pore channel 2 (TPC2) is upregulated in PAH, but its roles in PAH remain largely unknown. Our investigation aims at the mechanisms by which TPC2 regulates PAH development. We established an experimental PAH rat model via monocrotaline administration. Human and rat pulmonary arterial smooth muscle cells (PASMCs) were treated hypoxia as in vitro cell PAH models. The thickness of pulmonary arterial wall and obstructive arteriopathy in rats were examined. Autophagy was detected through TEM, and Ca2+ measurement and mRFP-GFP-LC3 transfection. The expression of α-SMA, LC3, p62, TPC2, HIF1α and STT3B were analyzed by qRT-PCR, western blot or IHC staining. The binding of HIF1α to TPC2 promoter was determined by ChIP-qPCR and EMSA assays. TPC2 glycosylation was evaluated by western blot. Transwell assay was applied to analyze cell migration. TPC2 expression was promoted and autophagy was inhibited in PAH rats and hypoxia-treated PASMCs. HIF1α directly bound to the promoter of TPC2, thus transcriptionally activating its expression in PAH rats and hypoxic PASMCs. Knockdown of TPC2 facilitated autophagic flux and repressed PASMC migration. STT3B enhanced TPC2 glycosylation in hypoxic PASMCs. Furthermore, Overexpression of TPC2 suppressed autophagic flux and promoted PASMC migration, but these effects were abrogated by STT3B knockdown or PNGase F, an eraser of N-linked glycans. Suppression of TPC2 enhanced autophagy and alleviated PAH in vivo. HIF1α-induced TPC2 transcription and subsequent STT3B-dependent TPC2 glycosylation inhibit autophagic flux and aggravate PAH. Our study suggests TCP2 as a potential therapeutic target for PAH.
- 28 December 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-16
Open AccessHypoxia-induced TPC2 transcription and glycosylation aggravates pulmonary arterial hypertension by blocking autophagy flux
Pulmonary arterial hypertension (PAH) is a serious medical condition that causes a failure in the right heart. Two-pore channel 2 (TPC2) is upregulated in PAH, but its roles in PAH remain largely unknown. Our investigation aims at the mechanisms by which TPC2 regulates PAH development. We established an experimental PAH rat model via monocrotaline administration. Human and rat pulmonary arterial smooth muscle cells (PASMCs) were treated hypoxia as in vitro cell PAH models. The thickness of pulmonary arterial wall and obstructive arteriopathy in rats were examined. Autophagy was detected through TEM, and Ca2+ measurement and mRFP-GFP-LC3 transfection. The expression of α-SMA, LC3, p62, TPC2, HIF1α and STT3B were analyzed by qRT-PCR, western blot or IHC staining. The binding of HIF1α to TPC2 promoter was determined by ChIP-qPCR and EMSA assays. TPC2 glycosylation was evaluated by western blot. Transwell assay was applied to analyze cell migration. TPC2 expression was promoted and autophagy was inhibited in PAH rats and hypoxia-treated PASMCs. HIF1α directly bound to the promoter of TPC2, thus transcriptionally activating its expression in PAH rats and hypoxic PASMCs. Knockdown of TPC2 facilitated autophagic flux and repressed PASMC migration. STT3B enhanced TPC2 glycosylation in hypoxic PASMCs. Furthermore, Overexpression of TPC2 suppressed autophagic flux and promoted PASMC migration, but these effects were abrogated by STT3B knockdown or PNGase F, an eraser of N-linked glycans. Suppression of TPC2 enhanced autophagy and alleviated PAH in vivo. HIF1α-induced TPC2 transcription and subsequent STT3B-dependent TPC2 glycosylation inhibit autophagic flux and aggravate PAH. Our study suggests TCP2 as a potential therapeutic target for PAH.
- Open Access
- 4 December 2024
- Published by Springer Nature in Respiratory Research
- Vol. 25 (1) , 1-17
T follicular helper cell is essential for M2 macrophage polarization and pulmonary vascular remodeling in hypoxia-induced pulmonary hypertension
Hypoxia-induced pulmonary hypertension (HPH) is a subgroup of type 3 pulmonary hypertension that may cause early right ventricular failure and eventual cardiac failure, which lacks potential therapeutic targets. Our previous research demonstrated that T follicular helper (TFH) cells that produce IL-21 were involved in HPH. However, the molecular mechanisms of TFH/IL-21-mediated pathogenesis of HPH have been elusive. Here we investigate the role of TFH cells and IL-21 in HPH. Studies were performed in C57BL/6 mice or IL-21 knockout mice exposed to chronic hypoxia to induce PH, and examined by hemodynamics. Molecular and cellular studies were performed in mouse lung and pulmonary arterial smooth muscle cells (PASMCs). M2 signature gene (Fizz1), M1 signature genes (iNos, IL-12β and MMP9), GC B cell and its marker GL-7, caspase-1, M2 macrophages, TFH cells, Bcl-6 and IL-21 level were measured. Proliferation rate of PASMCs was measured by EdU. Pyroptosis was assessed using Hoechst 33,342/PI double fluorescent staining. In response to chronic hypoxia exposure-induced pulmonary hypertension, IL-21−/− mice or downregulation of TFH cells in WT mice developed blunted pulmonary hypertension, attenuated pulmonary vascular remodelling. Furthermore, chronic hypoxia exposure significantly increased the germinal center (GC) B cell responses, which were not present in IL-21−/− mice or downregulation of TFH cells in WT mice. Importantly, IL-21 promoted the polarization of primary alveolar macrophages toward the M2 phenotype. Consistently, significantly enhanced expression of M2 macrophage marker Fizz1 were detected in the bronchoalveolar lavage fluid of HPH mice. Moreover, alveolar macrophages that had been cultivated with IL-21 promoted PASMCs proliferation and pyroptosis in vitro, while a selective CX3CR1 antagonist, AZD8797 (AZD), significantly attenuated the proliferation and pyroptosis of the PASMCs. Finally, ECM1 knockdown promoted IL-2–STAT5 signaling and inhibited Bcl-6 signaling to inhibit TFH differentiation in HPH. TFH/IL-21 axis amplified pulmonary vascular remodelling in HPH. This involved M2 macrophage polarization, PASMCs proliferation and pyroptosis. These data suggested that TFH/IL-21 axis may be a novel therapeutic target for the treatment of HPH.
- 4 December 2024
- Published by Springer Nature in Respiratory Research
- Vol. 25 (1) , 1-17
Open AccessT follicular helper cell is essential for M2 macrophage polarization and pulmonary vascular remodeling in hypoxia-induced pulmonary hypertension
Hypoxia-induced pulmonary hypertension (HPH) is a subgroup of type 3 pulmonary hypertension that may cause early right ventricular failure and eventual cardiac failure, which lacks potential therapeutic targets. Our previous research demonstrated that T follicular helper (TFH) cells that produce IL-21 were involved in HPH. However, the molecular mechanisms of TFH/IL-21-mediated pathogenesis of HPH have been elusive. Here we investigate the role of TFH cells and IL-21 in HPH. Studies were performed in C57BL/6 mice or IL-21 knockout mice exposed to chronic hypoxia to induce PH, and examined by hemodynamics. Molecular and cellular studies were performed in mouse lung and pulmonary arterial smooth muscle cells (PASMCs). M2 signature gene (Fizz1), M1 signature genes (iNos, IL-12β and MMP9), GC B cell and its marker GL-7, caspase-1, M2 macrophages, TFH cells, Bcl-6 and IL-21 level were measured. Proliferation rate of PASMCs was measured by EdU. Pyroptosis was assessed using Hoechst 33,342/PI double fluorescent staining. In response to chronic hypoxia exposure-induced pulmonary hypertension, IL-21−/− mice or downregulation of TFH cells in WT mice developed blunted pulmonary hypertension, attenuated pulmonary vascular remodelling. Furthermore, chronic hypoxia exposure significantly increased the germinal center (GC) B cell responses, which were not present in IL-21−/− mice or downregulation of TFH cells in WT mice. Importantly, IL-21 promoted the polarization of primary alveolar macrophages toward the M2 phenotype. Consistently, significantly enhanced expression of M2 macrophage marker Fizz1 were detected in the bronchoalveolar lavage fluid of HPH mice. Moreover, alveolar macrophages that had been cultivated with IL-21 promoted PASMCs proliferation and pyroptosis in vitro, while a selective CX3CR1 antagonist, AZD8797 (AZD), significantly attenuated the proliferation and pyroptosis of the PASMCs. Finally, ECM1 knockdown promoted IL-2–STAT5 signaling and inhibited Bcl-6 signaling to inhibit TFH differentiation in HPH. TFH/IL-21 axis amplified pulmonary vascular remodelling in HPH. This involved M2 macrophage polarization, PASMCs proliferation and pyroptosis. These data suggested that TFH/IL-21 axis may be a novel therapeutic target for the treatment of HPH.
- Open Access
- 1 May 2024
- Published by Elmer Press, Inc. in Journal of Clinical Medicine Research
- Vol. 16 (5) , 220-231
Association of Small Airway Functional Indices With Respiratory Symptoms and Comorbidity in Asthmatics: A National Cross-Sectional Study
Association of Small Airway Functional Indices With Respiratory Symptoms and Comorbidity in Asthmatics: A National Cross-Sectional Study
- 1 May 2024
- Published by Elmer Press, Inc. in Journal of Clinical Medicine Research
- Vol. 16 (5) , 220-231
Open AccessAssociation of Small Airway Functional Indices With Respiratory Symptoms and Comorbidity in Asthmatics: A National Cross-Sectional Study
Association of Small Airway Functional Indices With Respiratory Symptoms and Comorbidity in Asthmatics: A National Cross-Sectional Study
- 3 March 2024
- Published by Elsevier in The American Journal of Pathology
- Vol. 194 (6) , 989-1006
Ficolin-A/2 Aggravates Severe Lung Injury through Neutrophil Extracellular Traps Mediated by Gasdermin D–Induced Pyroptosis
- 3 March 2024
- Published by Elsevier in The American Journal of Pathology
- Vol. 194 (6) , 989-1006
Ficolin-A/2 Aggravates Severe Lung Injury through Neutrophil Extracellular Traps Mediated by Gasdermin D–Induced Pyroptosis
- 24 June 2023
- Published by Elsevier in International Immunopharmacology
- Vol. 121, 110548
Ficolin A knockout alleviates sepsis-induced severe lung injury in mice by restoring gut Akkermansia to inhibit S100A4/STAT3 pathway
- 24 June 2023
- Published by Elsevier in International Immunopharmacology
- Vol. 121, 110548
Ficolin A knockout alleviates sepsis-induced severe lung injury in mice by restoring gut Akkermansia to inhibit S100A4/STAT3 pathway
- 12 November 2022
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 210 (3) , 309-320
Exosome-transmitted S100A4 induces immunosuppression and non-small cell lung cancer development by activating STAT3
Non-small cell lung cancer (NSCLC) is the primary reason of tumor morbidity and mortality worldwide. We aimed to study the transfer process of S100A4 between cells and whether it affected NSCLC development by affecting STAT3 expression. First, S100A4 expression in NSCLC cells was measured. The exosomes in MRC-5, A549, and H1299 cells were isolated and identified. We constructed si-S100A4 and si-PD-L1 to transfect A549 cells and oe-S100A4 to transfect H1299 cells, and tested the transfection efficiency. Cell function experiments were performed to assess cell proliferation, clone number, apoptosis, cell cycle, migration, and invasion abilities. In addition, ChIP was applied to determine the targeting relationship between S100A4 and STAT3. Next, we explored NSCLC cell-derived exosomes role in NSCLC progress by transmitting S100A4. Finally, we verified the function of exosome-transmitted S100A4 in NSCLC in vivo. High expression of S100A4 was secreted by exosomes. After knocking down S100A4, cell proliferation ability was decreased, clones number was decreased, apoptosis was increased, G1 phase was increased, S phase was repressed, and migration and invasion abilities were also decreased. ChIP validated STAT3 and PD-L1 interaction. After knocking down S100A4, PD-L1 expression was decreased, while ov-STAT3 reversed the effect of S100A4 on PD-L1 expression. Meanwhile, S100A4 inhibited T-cell immune activity by activating STAT3. In addition, knockdown of PD-L1 inhibited cell proliferation, migration, and invasion. NSCLC cell-derived exosomes promoted cancer progression by transmitting S100A4 to activate STAT3 pathway. Finally, in vivo experiments further verified that exosome-transmitted S100A4 promoted NSCLC progression. Exosome-transmitted S100A4 induces immunosuppression and the development of NSCLC by activating STAT3.
- 12 November 2022
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 210 (3) , 309-320
Exosome-transmitted S100A4 induces immunosuppression and non-small cell lung cancer development by activating STAT3
Non-small cell lung cancer (NSCLC) is the primary reason of tumor morbidity and mortality worldwide. We aimed to study the transfer process of S100A4 between cells and whether it affected NSCLC development by affecting STAT3 expression. First, S100A4 expression in NSCLC cells was measured. The exosomes in MRC-5, A549, and H1299 cells were isolated and identified. We constructed si-S100A4 and si-PD-L1 to transfect A549 cells and oe-S100A4 to transfect H1299 cells, and tested the transfection efficiency. Cell function experiments were performed to assess cell proliferation, clone number, apoptosis, cell cycle, migration, and invasion abilities. In addition, ChIP was applied to determine the targeting relationship between S100A4 and STAT3. Next, we explored NSCLC cell-derived exosomes role in NSCLC progress by transmitting S100A4. Finally, we verified the function of exosome-transmitted S100A4 in NSCLC in vivo. High expression of S100A4 was secreted by exosomes. After knocking down S100A4, cell proliferation ability was decreased, clones number was decreased, apoptosis was increased, G1 phase was increased, S phase was repressed, and migration and invasion abilities were also decreased. ChIP validated STAT3 and PD-L1 interaction. After knocking down S100A4, PD-L1 expression was decreased, while ov-STAT3 reversed the effect of S100A4 on PD-L1 expression. Meanwhile, S100A4 inhibited T-cell immune activity by activating STAT3. In addition, knockdown of PD-L1 inhibited cell proliferation, migration, and invasion. NSCLC cell-derived exosomes promoted cancer progression by transmitting S100A4 to activate STAT3 pathway. Finally, in vivo experiments further verified that exosome-transmitted S100A4 promoted NSCLC progression. Exosome-transmitted S100A4 induces immunosuppression and the development of NSCLC by activating STAT3.